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ABSTRACT
Introduction: Age-related immunosenescence influences the presentation of tuberculosis (TB) in older
patients. Here, we explore the clinical and radiological presentation of TB in the elderly and the factors
associated with time to treatment for TB.
Methods: This is a retrospective cohort study comparing the clinical, radiological and demographic
characteristics of TB patients aged ⩾65 years with TB patients aged 18–64 years in a large cohort of TB
patients in the UK. Factors associated with the time to presentation and time to treatment were identified
using a multivariable analysis model.
Results: 1023 patients were included in the analyses: 679 patients aged 18–64 years and 344 patients aged
⩾65 years. “Classical” symptoms of TB (cough, haemoptysis, fever, nights sweats and weight loss) were less
common among older patients with pulmonary TB (PTB) (p<0.05), but dyspnoea was more common
among older patients (p=0.001). Time from presenting in secondary care to starting treatment was shorter
in younger compared with older patients: 3 versus 15 days (p=0.001). When adjusted for age, factors
associated with shorter time to treatment from symptom onset include sex (male versus female) (hazard
ratio (HR) 1.23 (95% CI 1.05–1.46)), UK born (HR 1.23 (95% CI 1.05–1.46)) and HIV (HR 2.07 (95% CI
1.30–3.29)). Only age remained an independent predictor of time to treatment in a multivariable model
(HR 0.98 (95% CI 0.98–0.99)). For those with PTB, chest radiography findings showed that cavitation and
lymphadenopathy were more common among younger patients (p=0.001).
Conclusions: Older patients aged ⩾65 years with TB had fewer “classical” clinical and radiological
presentations of TB, which may explain longer times to starting treatment from symptom onset compared
with younger patients aged <65 years.
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Introduction
Age-related changes to the innate and adaptive immune system can increase susceptibility to tuberculosis
(TB) infection or the reactivation of latent TB infection (LTBI) in older patients [1]. The global increase in
ageing means that those aged ⩾65 years are expected to account for 16% of the world’s population by
2050, a proportion expected to rise much faster in developing countries (a 250% increase) compared with
developed countries (a 71% increase) [2]. More than 95% of the burden of TB is in low- and
middle-income countries (LMICs) [3, 4], with the older population increasing as a proportion of patients
with TB [5, 6]. There is also likely to be a burden of undetected TB among the elderly, particularly in
LMICs [4]. For older patients, the higher rate of TB is likely a combination of cumulative years with LTBI,
age-related immunosenescence, comorbidities and immunosuppressive therapy [4].
TB in the elderly presents with fewer of the classical symptoms of TB [1, 6–9], less specific radiological
changes [10, 11] and more comorbidities [9, 12] than in younger patients, and it has even been proposed
that TB in older adults should be considered as a different disease entity [13]. The classical TB symptoms
of cough, haemoptysis, fever, drenching night sweats and weight loss may not be as evident in older
patients. Less specific symptoms, such as weakness, dyspnoea, anorexia and mental change, are seen more
frequently in older patients with TB compared with younger patients [1, 13, 14]. In addition,
comorbidities that are more common in older patients may mask the symptoms of TB, e.g. those with
chronic cough due to chronic obstructive pulmonary disease (COPD) may have a delayed presentation or
diagnosis. However, conversely, they may have closer healthcare contact.
UK surveillance data show that the proportion of TB patients who experienced a delay of >4 months from
symptom onset to starting treatment increases with age, from 24.9% in those aged 15–44 years to 38.6%
among those aged ⩾65 year olds [15]. The reasons for this are numerous, and likely relate to a
combination of patient-related and health system delays. Patient-related delay refers to the time from
symptom onset to first seeking healthcare, whereas provider delay occurs within the healthcare system
[16]. The less typical symptomatology and radiology among the elderly contributed to patient and
healthcare system-related delays in some [10, 17, 18] but not all cohorts [19, 20]. For patient-related
delays, there may be challenges to recall of type and duration of symptoms on presenting either to
secondary care; this may be disproportionately affect older compared with younger patients with TB.
There are few recent studies that explore the differences between older and younger TB patients in a UK
setting. TB in older adults is increasingly important given ageing in LMICs where the burden of TB is
greatest. It is associated with comorbidities and polypharmacy, increased side-effects, and poorer
outcomes, thereby placing increased demand per patient on clinical services [21]. In this study, we
compare the clinical and radiological presentation of TB in adult patients aged 18–64 or ⩾65 years and
factors (including age) associated with time to diagnosis and treatment in a London-based cohort. This
cohort represents a high TB burden area in an otherwise low TB incidence country, which may be similar
to other urban areas in Western Europe.
Methods
Study design
We undertook a retrospective study comparing patients aged ⩾65 years with patients aged 18–64 years.
The aim was to compare the clinical and radiological features at presentation to secondary care, the
duration of symptoms at presenting to secondary care, the time from presentation to secondary care to
starting treatment and the total time from symptom onset to starting treatment between the two groups.
Factors that may influence time to presentation and treatment were examined: age, ethnicity, place of birth
(UK born versus non-UK born), sex, comorbidities (diabetes, renal failure, cancer, HIV and respiratory
conditions, including COPD, asthma, bronchiectasis and pulmonary fibrosis). In addition, we also
analysed differences by site of TB (extrapulmonary TB (EPTB) versus pulmonary TB (PTB)) and PTB
smear status.
Study site and patient cohort
A list of all patients treated for TB at Northwick Park Hospital (London, UK) between 2002 and 2015 was
downloaded from the London TB Register. All TB patients aged ⩾65 years who began treatment from
January 1, 2002 to December 31, 2015 were included. We randomly selected a twofold larger sample of
patients aged 18–64 years from the register for the period 2011–2015 (because clinical data recording
improved from 2011 onwards). Northwick Park Hospital is part of London North West Healthcare NHS
Trust, which has one of the largest TB units in the UK (and in Western Europe), treating 600 TB patients
per year during 2010–2014.
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Data collection
The following data were extracted from electronic records in secondary care: symptoms (nature of
symptoms and symptom duration at presentation to secondary care, including presence of cough,
haemoptysis, fever, drenching night sweats, weight loss, dyspnoea, lethargy and reduced appetite), clinical
(site or sites of TB) and baseline radiology (chest radiograph most closely preceding start of treatment
with features including cavitation, consolidation, nodules, miliary, lymphadenopathy and effusion). For
radiology, data were extracted from reports when each of the parameters of interest was reported.
Cavitations imply the presence of a cavity; nodules are small masses of tissue visible seen on chest
radiography; miliary refers to the presence of uniformly distributed 1–3 mm diameter nodules on chest
radiography.
Data were also collected on baseline biochemistry and haematology (full blood count, erythrocyte
sedimentation rate, renal function, electrolytes, albumin, alanine aminotransferase, alkaline phosphatase,
bilirubin and 25-hydroxy-vitamin D level), and treatment (time to starting treatment and symptom onset
to starting treatment). Access to primary care records was not possible except where referral letters were
uploaded onto the secondary care system.
Baseline biochemical and haematological data were extracted from medical records for groups of patients
aged ⩾65 and 25–35 years. Data from patients aged 25–35 years were chosen in order to compare elderly
patients with patients in the age range representing the majority of TB patients in our centre.
Time to presentation and start of treatment
To investigate possible age-related delays in treatment and other factors potentially associated with
treatment delays, time periods were classified as: 1) pre-secondary care (i.e. before first attendance at
hospital), encompassing patient-related and primary healthcare factors, hereafter referred to as “time to
presentation” (this period is affected by recall bias of what is reported by the patient either in primary care
or secondary care and what is recorded in the primary care referral letter to secondary care); 2)
post-secondary care (i.e. after attendance at hospital), describing the period between being first seen at
secondary care to starting treatment for TB, hereafter referred to as “time from presentation” (this includes
time for investigations); and 3) total time from symptom onset to commencing TB treatment, hereafter
referred to as “time to treatment”. These chosen time periods encompass the patient’s journey from
symptom onset to starting treatment and allow for comparison with published literature.
Statistical analysis
Baseline (at time of admission) demographic and clinical characteristics of patients aged ⩾65 years were
compared with characteristics of patients aged 18–64 years using the Chi-squared test (or Fisher’s exact
test for cell frequencies <5) for categorical variables (α=0.05) and the Kruskal–Wallis test for continuous
variables (α=0.05).
Time periods were presented as median (interquartile range (IQR)) and were also categorised into <2, 2–4
and >4 months. Differences between age groups were tested using the Chi-squared, Fisher’s exact and
Kruskal–Wallis tests, and were presented using Kaplan–Meier survival curves (with the log-rank test). Cox
regression was used to investigate factors associated with each time period. Associations were expressed as
hazard ratios (HRs), with HR >1 indicating a faster rate (shorter time) and HR <1 indicating a slower rate
(longer time). Univariate and age-adjusted models (using age as a continuous exposure variable) were
fitted, and factors that had evidence (p<0.1) of an association with time period (after adjustment for age)
were carried forward to a (fully adjusted) multivariable model. All models were probability weighted to
take into account sampling from the patient population aged 18–64 years.
Statistical analyses were performed using Stata version 13 (StataCorp, College Station, TX, USA).
Ethics
Ethics were reviewed by the Research and Development Dept of London North West Healthcare NHS
Trust. Given the retrospective nature of the data, which were collected from routine clinical practice, the
recommendation was that research ethics approvals from the Health Research Authority were not required.
Results
Patient characteristics
Age, ethnicity and place of birth
1023 patients were included in the analyses: 679 patients aged 18–64 years and 344 patients aged
⩾65 years (table 1).
61.6% of the younger group and 56.7% in the older group were male (p=0.13). Ethnicity was distributed
differently across the two age groups (p=0.001): South Asian ethnicity (Indian, Afghani, Nepalese,
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Pakistani and Sri Lankan) accounted for 76.9% of cases in younger patients and 67.8% of cases in older
patients, while the proportion of White patients was 6.2% in the younger cohort and 15.4% in the older
cohort.
Biochemistry and vitamin D levels
There was evidence of differences in all biochemistry measures except bilirubin. Vitamin D levels differed
significantly between the two groups, but both were low at a median of 1 and 6 nmol·L−1 for younger and
older patients, respectively. Only 0.4% of patients aged <65 years versus 17.6% of patients aged ⩾65 years
had a vitamin D level >50 nmol·L−1.
TABLE 1 Baseline characteristics in older (age ⩾65 years) versus younger (18–64 years)
patients with tuberculosis (TB)
Younger patients
(18–64 years)
Older patients
(⩾65 years)
p-value
Patients 679 344
Age years 31 (26–42) 73 (69–78)
Sex 0.13
Female 261 (38.4) 149 (43.3)
Male 418 (61.6) 195 (56.7)
Ethnicity 0.001
Afghani 11 (1.6) 9 (2.6)
Black 89 (13.1) 44 (12.8)
Indian 437 (64.4) 193 (56.1)
Nepalese 25 (3.7) 6 (1.7)
Pakistani 32 (4.7) 14 (4.1)
Sri Lankan 17 (2.5) 11 (3.2)
White 42 (6.2) 53 (15.4)
Other 26 (3.8) 14 (4.1)
UK born 56 (8.2) 39 (11.4) 0.10
HIV positive 12 (2.8) n=431 1 (0.9) n=112 0.24
Site of TB
Pulmonary 243 (35.8) 169 (49.1)
Extrapulmonary 436 (64.2) 175 (50.8) 0.001
Pleural 74 (10.9) 45 (13.1) 0.30
Intrathoracic lymph node 117 (17.2) 46 (13.4) 0.11
Extrathoracic lymph node 218 (32.1) 63 (18.3) 0.001
Gastrointestinal 49 (7.2) 20 (5.8) 0.39
Central nervous system 20 (3.0) 11 (3.2) 0.82
Spinal 46 (6.8) 27 (7.9) 0.53
Miliary 13 (1.9) 15 (4.4) 0.02
Culture results
M. tuberculosis culture positive
(all cases)
388 (65.4) 177 (61.0) 0.20
M. tuberculosis culture positive
(PTB)
162 (73.0) 100 (69.0) 0.41
Smear positive (PTB) 67 (29.1) 33 (25.0) 0.40
Biochemistry
ESR mm·h−1 33 (13–67) n=273 28 (18–72) n=205 0.04
Albumin g·L−1 37 (31–39) n=318 33 (28–39) n=287 <0.001
ALT IU·L−1 21 (14–36) n=317 19 (12–29) n=287 0.007
ALT >50 IU·L−1 41 (12.9) n=317 34 (9.9) n=345
ALP IU·L−1 91 (77–112) n=318 96 (79–128) n=287 0.005
Bilirubin µM·L−1 8 (6–11) n=312 8 (6–12) n=285 0.77
Sodium mmol·L−1 138 (136–140) n=317 137 (133–140) n=286 0.001
Creatinine µM·L−1 63 (57–69) n=317 86 (68–105) n=286 <0.001
Creatinine >112 µM·L−1 3 (0.9) n=318 71 (22.2) n=320 <0.05
Vitamin D nmol·L−1 1 (1–8) n=275 6 (1–31) n=205 0.001
Vitamin D >50 nmol·L−1 1 (0.4) n=275 36 (17.6) n=205 0.001
Data are presented as n, median (interquartile range) or n (%), unless otherwise stated. M. tuberculosis:
Mycobacterium tuberculosis; PTB: pulmonary TB; ESR: erythrocyte sedimentation rate; ALT: alanine
aminotransferase; ALP: alkaline phosphatase.
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Site of TB
35.8% of younger patients and 49.1% of older patients had PTB (p=0.001) (table 1 and figure 1).
Extrathoracic TB lymphadenitis was less common (18.3% versus 32.1%; p=0.001) and miliary TB more
common (4.4% versus 1.9%; p=0.02) in older compared with younger EPTB patients.
Clinical symptoms
The “classical” symptoms of TB, including cough, haemoptysis, fever, drenching night sweats and weight
loss, were more common among PTB patients in the younger cohort (p<0.05) (table 2). When EPTB
patients were included the differences remained for cough, fever, drenching night sweats and dyspnoea,
but not for haemoptysis and weight loss. The less specific symptoms of dyspnoea, lethargy and reduced
appetite were more common among older patients when all sites of TB were included, but only dyspnoea
was statistically significant.
Radiology
There were some differences in the chest radiography appearance of PTB patients: cavitation was more
common among younger than older patients (18.3% versus 10.3%; p=0.001), as was lymphadenopathy
(19.5% versus 4.1%; p=0.001). Apparent differences in nodules (16.1% versus 10.3%) and effusions (13.7%
versus 7.2%) were not supported by statistical evidence (table 3). Miliary TB was seen more frequently in
older patients (4.1% versus 2.9%) and mirrored the rates of clinically classified miliary TB. Around half of
the patients in both groups had consolidation on their chest radiographs.
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FIGURE 1 Site of tuberculosis (TB) in the younger group (aged 18–64 years) and the older group (aged
⩾65 years): pulmonary TB (PTB) versus extrapulmonary TB (EPTB), with specific sites for EPTB also shown.
ITLN: intrathoracic lymph node; ETLN: extrathoracic lymph node; GI: gastrointestinal; CNS: central nervous
system. *: p<0.05.
TABLE 2 Symptoms at presentation of the younger group (aged 18–64 years) and the older group (aged ⩾65 years) with
tuberculosis (TB) and pulmonary TB (PTB)
All TB patients PTB patients
Younger patients
(18–64 years)
Older patients
(⩾65 years)
p-value Younger patients
(18–64 years)
Older patients
(⩾65 years)
p-value
Patients 629 136 218 72
Cough 236 (37.5) 38 (27.9) 0.035 140 (64.2) 31 (43.1) 0.002
Haemoptysis 32 (5.1) 2 (1.5) 0.063 27 (12.4) 2 (2.8) 0.03
Fever 194 (30.8) 18 (13.2) 0.001 84 (38.5) 11 (15.2) 0.001
Drenching night sweats 159 (25.3) 12 (8.8) 0.001 72 (33) 7 (9.7) 0.001
Weight loss 226 (36.0) 42 (30.9) 0.26 113 (51.8) 27 (37.5) 0.04
Dyspnoea 37 (5.9) 28 (20.6) 0.001 22 (10.1) 21 (29.2) 0.001
Lethargy 30 (4.8) 10 (7.4) 0.22 9 (4.1) 6 (8.3) 0.16
Reduced appetite 37 (5.9) 16 (11.8) 0.70 18 (8.3) 7 (9.7) 0.70
Data are presented as n or n (%), unless otherwise stated.
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Timing of events
Time to presentation (from symptom onset)
Considering all cases of TB, the median duration of symptoms at presentation to secondary care was
longer in older patients (60 days) compared with younger patients (45 days), but this difference was not
supported by statistical evidence (p=0.3). 27.5% of older patients were symptomatic for >4 months
compared with 21.0% of younger patients (p=0.53).
For PTB, the median duration of symptoms was 60 days in younger patients compared with 75 days in
older patients, but this was not statistically significant (p=0.40). For pleural, intrathoracic and extrathoracic
lymph node TB, the median duration in younger patients was 30, 30 and 50 days, respectively, and for
older patients it was 26, 30 and 60 days, respectively (supplementary table S1).
Time from presentation (to starting treatment)
For all TB cases, the median time from presenting in secondary care to starting treatment was shorter in
younger compared with older patients: 3 versus 15 days (p=0.001). For those with PTB, the median
duration was 2 versus 7 days in younger versus older patients (p=0.001). The time to starting treatment for
EPTB was also longer in older patients. For pleural, intrathoracic and extrathoracic lymph node TB, the
median time in younger patients was 3, 18 and 5 days, respectively, and for older patients it was 29, 42
and 11 days, respectively.
Time to treatment (from symptom onset)
Total time from symptom onset to starting treatment was 50% longer for older patients (91 days) than for
younger patients (61 days) (p=0.001) for all patients with TB. The findings for those with PTB alone were
similar at 61 versus 92.5 days in younger versus older patients with PTB (table 4). The total time from
symptom onset to starting treatment was longer for older patients with EPTB. For pleural, intrathoracic
and extrathoracic lymph node TB, the median time in younger patients was 35, 63 and 61 days,
respectively, and for older patients it was 54, 84 and 94 days, respectively.
Across age groups
Symptom duration at presentation to secondary care, time to starting treatment from presentation to
secondary care and total time to start treatment from symptom onset to starting treatment are shown
across age groups in figure 2. The median (IQR) time from secondary care to treatment for patients aged
65–74, 75–84 and 85–94 years was 18.5 (4–60), 13 (3–54) and 9 (2–36) days, respectively, compared with
6 (1–32) days for patients aged 55–64 years.
Factors associated with time to treatment
Age (as a continuous variable) was associated with longer time to presentation at secondary care (HR 0.98
(95% CI 0.98–0.99) per year of age) (table 5), longer time to starting treatment (HR 0.98 (95% CI
0.98–0.99) per year of age) (table 6) and longer time from symptom onset to starting treatment (HR 0.98
(95% CI 0.98–0.99) per year of age) (table 7). These associations were unchanged in multivariable models
when adjusted for other factors.
TABLE 3 Radiological differences between younger (aged 18–64 years) and older (aged
⩾65 years) patients with pulmonary tuberculosis (PTB)
Younger patients
(18–64 years)
Older patients
(⩾65 years)
p-value
Patients 679 344
Patients with PTB 243 (35.7) 169 (49.1) 0.001
Patients with PTB with chest radiography reports 241 (99.2) 97 (57.4)
Chest radiography changes
Cavitation 44 (18.3) 10 (10.3) 0.001
Consolidation 116 (48.1) 49 (50.5) 0.692
Nodules 39 (16.1) 10 (10.3) 0.165
Miliary 7 (2.9) 4 (4.1) 0.568
Lymphadenopathy 47 (19.5) 4 (4.1) 0.001
Effusion 33 (13.7) 7 (7.2) 0.095
Data are presented as n or n (%), unless otherwise stated.
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When adjusted for age, the factors associated with a shorter time to presentation at secondary care were
sex (male versus female) (HR 1.20 (95% CI 1.03–1.34)), HIV (HR 2.08 (95% CI 1.31–3.30)) and PTB
versus EPTB (HR 1.17 (95% CI 1.00–1.37)). Of these factors, only age and PTB versus EPTB remained as
independent predictors in a multivariable model (HR 1.26 (95% CI 1.05–1.50)) (table 5).
When adjusted for age, factors associated with a shorter time from presentation to secondary care
included sex (male versus female), positive sputum smear, hypertension, cough, sweats and weight loss. A
shorter time from presentation to starting treatment was associated with PTB versus EPTB. In a
multivariable model, only age and sweats remained as independent predictors (table 6).
When adjusted for age, factors associated with a shorter time to treatment (from symptom onset) included
sex (male versus female) (HR 1.23 (95% CI 1.05–1.46)), UK born (HR 1.23 (95% CI 1.05–1.46)) and HIV
(HR 2.07 (95% CI 1.30–3.29)). Only age remained as an independent predictor in a multivariable model
adjusted for each of these variables (table 7).
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FIGURE 2 Symptom duration at presentation to secondary care, time to starting treatment from presentation
to secondary care and total time to starting treatment from symptom onset. **: p<0.01.
TABLE 4 Symptom duration at presentation to secondary care, time to starting treatment from presentation to secondary care
and total time to starting treatment from symptom onset among older (aged ⩾65 years) and younger (18–64 years) patients
with tuberculosis (TB) and pulmonary TB (PTB)
Younger patients
(18–64 years)
Older patients
(⩾65 years)
p-value all
patients
p-value PTB
patients
All TB patients PTB patients All TB patients PTB patients
Patients 523 182 109 53
Symptom duration at presentation to
secondary care days
45 (22.5–90) 60 (30–90) 60 (15–135) 75 (11–180) 0.30 0.40
Symptom duration
<2 months 257 (39.1) 51 (46.8) 0.66
2–4 months 156 (39.9) 28 (25.7) 0.39
>4 months 110 (21.0) 30 (27.5) 0.16
Time to starting treatment from
presentation to secondary care to days
3 (1–18) 2 (1–6) 15 (3–59) 7 (2–53) 0.001 0.001
Total time to starting treatment from
symptom onset days
61 (31–96) 61 (31–103) 91 (46–182) 92.5 (41.5–189) 0.001 0.003
Time to treatment n=506 n=164 n=102 n=49
<2 months 269 (53.2) 75 (45.7) 34 (33.3) 17 (34.7) 0.001 0.001
<4 months 405 (80.0) 128 (78.0) 66 (64.7) 31 (63.3)
>4 months 101 (20.0) 36 (22.0) 36 (35.3) 18 (36.7)
Data are presented as n, median (interquartile range) or n (%), unless otherwise stated.
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Discussion
In this cohort, older age was associated with a longer time from symptom onset to starting treatment for
TB. Symptom duration at presentation to secondary care did not differ between the two groups and the
overall difference was attributed to longer time to starting treatment after presentation to secondary care.
A greater proportion of older patients were symptomatic for >4 months compared with younger patients.
The clinical and radiological presentations of older patients were different to younger patients with TB:
older patients had fewer of the “classical” symptoms of TB and more non-TB specific symptoms, including
dyspnoea and lethargy. Cavitation, nodules, lymphadenopathy and effusions were more common on chest
radiography in younger than in older patients.
The higher proportion of South Asian patients noted in the younger age group with active TB is likely to
represent trends in immigration to the UK, where we typically observe the phenomenon of young Asian
males living in low-rental areas of London where there is a community of their compatriots and having
full-time or part-time low-paid jobs in food or other factories or in construction. This and the peak of TB
in this age group may give a biased perception of the “typical” patient with TB in the UK, perhaps
contributing to a lower index of clinical suspicion of TB in older or White patients. Public Health England
reported that 25% of patients with PTB commenced treatment at least 4 months after symptom onset, but
this proportion increased to 33% of UK-born cases and 35% of those aged ⩾65 years [22].
The difference in clinical presentation has been borne out in other studies in Turkey [6, 23], although
some report a similar prevalence of respiratory symptoms [24]. The differences in clinical and radiological
presentations are likely as a result of the effect of immunosenescence on the characteristics of TB in older
compared with younger patients with TB; similar distortions occur in other immunocompromised states,
e.g. HIV [25]. It has long been hypothesised that TB in the elderly results from reactivation of LTBI rather
than recently acquired infection. TB prevalence in England before the advent of chemotherapy in the
1950s was high and UK-born older patients may have developed LTBI in childhood or early adulthood
[26]. Changes relating to immunosenescence, or the onset of comorbidities which influence the immune
system, may contribute to reactivation [1, 12, 13, 27]. Generally, LTBI reactivation is most likely to occur
within 18 months of exposure [28]. This is unlikely to be the case in our older patients, because rates of
transmission of TB in London are low [22]. The exception may be where the elderly live in a closed
environment, with nursing home residents having an increased risk of TB [29]. Some older studies that
describe drug resistance across age groups show that monoresistance (to isoniazid or streptomycin) in
TABLE 5 Factors associated with time to presentation (symptom duration) at secondary care
Crude HR (95% CI) Age-adjusted HR (95% CI) Fully adjusted HR (95% CI)#
Age 0.98 (0.98–0.99) 0.98 (0.98–0.99)
Sex (male versus female) 1.19 (1.03–1.38) 1.20 (1.03–1.34) 0.85 (0.71–1.02)
Ethnic group
Indian 1.08 (0.85–1.37)
Pakistani 1.10 (0.79–1.53)
Afghani 0.58 (0.46–0.73)
White 0.78 (0.55–1.10)
Bangladeshi 1.03 (0.62–1.72)
Black 0.91 (0.67–1.22)
Chinese 4.27 (3.22–5.67)
HIV 1.50 (0.93–2.42) 2.08 (1.31–3.30) 0.71 (0.46–1.09)
Diabetes 1.26 (1.01–1.58) 1.09 (0.85–1.40)
Hypertension 1.19 (0.96–1.46) 1.01 (0.80–1.30)
Renal failure 1.11 (0.90–1.37)
Cancer 1.33 (0.82–2.16)
Lung disease
Asthma/COPD 1.59 (0.58–4.33)
Bronchiectasis 1.28 (0.54–3.00)
ILD 1.09 (0.33–3.65)
PE 4.04 (1.48–11.00)
PTB versus EPTB 1.20 (1.03–1.38) 1.17 (1.00–1.37) 1.26 (1.05–1.50)
HR: hazard ratio; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; PE:
pulmonary embolism; PTB: pulmonary tuberculosis; EPTB: extrapulmonary tuberculosis. #: adjusted for
age, sex, HIV and PTB versus EPTB.
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older patients is only slightly lower than in younger patients, suggesting that recent transmission may be
important [30, 31].
In our study, we find that EPTB is significantly more common among younger patients than PTB (64%
versus 35%) compared with ∼50% of each among older patients. There is some tentative evidence in the
literature that PTB is more common than EPTB among older patients, which would be consistent with TB
in the elderly being predominantly as a result of reactivation. TEALE et al. [32] reported that PTB
accounted for 87% of cases in the elderly compared with 75% of cases in younger patients in the UK.
Another study (in India) found PTB to be similar at 75% in older patients and 73% in younger patients;
the most common site of EPTB in older patients was TB lymphadenitis [9]. The different ratios of EPTB
and PTB in older and younger patients in our cohort is possibly related to the pattern of reactivation and
differences of presentation of TB resulting from immunosenescence related to ageing [33]. There are few
phylogenetic studies that characterise this in older populations. A Japanese variable number tandem repeat
study analysed 387 strains of Mycobacterium tuberculosis among elderly patients and found that 9.7% of
the cases were attributable to recent transmission; this supports the suggestion that TB in this population
is as a result of endogenous reactivation from infection at a time when TB was more prevalent [34].
Another explanation for the difference may also relate to differences in dominant ethnicities, with South
Asian ethnicity more common in the younger age group compared with White ethnicity in the older age
group; both age and ethnicity have been shown to influence the site of TB, with EPTB being more
common among ethnicities from outside of Europe [35].
There are few studies that compare treatment delays in the UK between younger and older patients. LEWIS
et al. [36] found an overall delay of 126 days, which is longer than in our cohort; the median duration of
symptoms was similar at 63 days, but the healthcare delay was longer at 35 days. The contribution of
primary versus secondary care delays was not clarified, making direct comparison with our study difficult.
TABLE 6 Factors associated with time to starting treatment (from presentation to secondary
care)
Crude HR (95% CI) Age-adjusted HR (95% CI) Fully adjusted HR (95% CI)#
Age 0.98 (0.98–0.99) 0.98 (0.98–0.99)
Sex (male versus female) 1.17 (1.01–1.35) 1.19 (1.01–1.38) 1.09 (0.94–1.29)
Ethnic group
Indian 1.03 (0.84–1.26)
Pakistani 0.75 (0.49–1.17)
Afghani 0.24 (0.19–0.29)
White 0.90 (0.63–1.28)
Bangladeshi 1.16 (0.61–2.21)
Black 0.94 (0.71–1.24)
Chinese 0.89 (0.49–1.64)
UK born 0.96 (0.71–1.31) 1.00 (0.72–1.40)
Sputum smear 1.09 (1.01–1.18) 1.10 (1.01–1.20) 1.09 (0.90–1.32)
TB sensitivity 1.27 (1.11–1.44) 0.84 (0.70–1.01)
HIV 1.03 (0.74–1.43)
Diabetes 1.36 (1.13–1.64) 1.14 (0.92–1.40)
Hypertension 1.55 (1.29–1.87) 1.33 (1.06–1.67) 0.86 (0.65–1.12)
Renal failure 1.28 (1.13–1.46) 1.16 (0.99–1.35)
Cancer 1.54 (1.20–1.97) 1.23 (0.90–1.69)
Lung disease
Asthma/COPD 0.83 (0.29–2.37)
Bronchiectasis 3.16 (0.99–10.1)
ILD 1.27 (0.39–4.19)
PE 1.22 (3.91–3.78)
Sarcoid 1.10 (0.42–2.90)
PTB versus EPTB 0.74 (0.64–0.86) 0.70 (0.60–0.82) 1.10 (0.90–1.34)
Cough 1.22 (1.06–1.40) 1.22 (1.06–1.41) 0.97 (0.81–1.15)
Sweats 1.38 (1.18–1.61) 1.33 (1.12–1.56) 1.24 (1.02–1.51)
Weight loss 1.24 (1.08–1.43) 1.25 (1.08–1.44) 1.03 (0.87–1.22)
HR: hazard ratio; TB: tuberculosis; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung
disease; PE: pulmonary embolism; PTB: pulmonary tuberculosis; EPTB: extrapulmonary tuberculosis.
#: adjusted for age, sex, sputum smear, hypertension, PTB versus EPTB, cough, sweats and weight loss
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Another UK study found that female sex and older age were contributors to delays in starting treatment
[37]. Of note, we did not find ethnicity to be a cause of delay; however, the numbers of White patients in
this study are small (42 in those aged 18–65 years and 53 in those aged ⩾65 years), which may account for
this. Time to starting treatment from presentation to secondary care was shorter for EPTB compared with
PTB in this cohort, which differs from published studies [38]. This is likely due to the rapidity with which
diagnostics are carried out and treatment initiated in EPTB patients at this site, e.g. lymph node or pleural
aspirate compared with awaiting sputum samples or bronchoalveolar lavage for patients with PTB.
A UK study using data routinely collected between 1999 and 2000 showed that White ethnicity, female sex
and older age contributed to delays in the West Midlands [39]. A North London study in 2004 reported
delays between 78 and 99 days, comprising patient-related delays of 35–54 days and healthcare system
delays of 30 days. Shorter delays occurred in patients from high-prevalence countries, younger patients and
those with smear-positive disease [40]. The difference in time to starting treatment may relate to the more
classical symptoms of TB evident in younger patients or the absence of comorbidities that alter the course
of TB. Concerns about drug interactions, polypharmacy or drug side-effects in older patients may
influence the decision to start TB treatment.
TB mortality increases with age [41]. In 2015, there were 1.8 million TB-related deaths worldwide [42]; in
2014, in the UK, of the 6405 with sensitive TB, 5.5% had death as an outcome [22], with those aged
⩾65 years accounting for 66.4% of deaths [22]. According to the 2010 Global Burden of Disease estimates,
>50% of TB deaths occur in those aged ⩾65 years internationally [4]. In the UK, those aged ⩾65 years
accounted for 66.4% of 351 deaths [22]. In a Chinese study, those aged ⩾65 years had twice the risk of
death as those aged 18–64 years [43]. In the UK, deaths are broken down to further categories, as older
patients may also die of other causes where TB is not the main cause, may be a contributor or may not be
contributing [22]. However, the higher proportion of deaths accounted for by older patients with TB
supports the need to invest in measures to ensure the appropriate investigation and management of older
patients with TB.
A constraint of this study is that presentation at secondary care rather than primary care is taken as the
time-point for presenting to healthcare, because this was readily available from the databases. There may
have been more incorrectly recorded data for older patients (because we used data from 2002 to 2015), but
this is unlikely to bias our measures of effect. Bias could have occurred in relation to recall of time of
symptom onset, if older patients tended to recall longer or shorter time since onset. This can be hard to
TABLE 7 Factors associated with time to starting treatment from symptom onset
Crude HR (95% CI) Age-adjusted HR (95% CI) Fully adjusted HR (95% CI)#
Age 0.98 (0.98–0.99) 0.98 (0.98–0.99)
Sex (male versus female) 1.22 (1.04–1.43) 1.23 (1.05–1.46) 0.85 (0.72–1.00)
Ethnic group 0.98 (0.94–1.02) 0.98 (0.95–1.02)
UK born 0.92 (0.67–1.27) 1.23 (1.05–1.46) 1.05 (0.77–1.43)
Sputum smear 0.98 (0.90–1.07) 0.97 (0.88–1.06)
TB sensitivity 1.14 (0.99–1.32) 0.98 (0.82–1.18)
HIV 1.37 (0.93–2.02) 2.07 (1.30–3.29) 0.71 (0.46–1.07)
Diabetes 1.55 (1.21–1.99) 1.26 (0.97–1.64)
Hypertension 1.40 (1.13–1.73) 1.14 (0.90–1.44)
Renal failure 1.22 (0.99–1.51) 1.11 (0.86–1.45)
Cancer 1.27 (0.82–1.98)
Lung disease
Asthma/COPD 1.78 (0.67–4.69)
Bronchiectasis 2.26 (0.74–6.90)
ILD 1.41 (0.32–6.16)
PE 5.64 (1.87–17.01)
Sarcoid 28.2 (5.91–124.76)
PTB versus EPTB 1.01 (0.93–1.30)
Cough 1.07 (0.91–1.25)
Sweats 1.22 (1.03–1.44) 1.15 (0.97–1.37)
Weight loss 0.90 (0.77–1.05)
HR: hazard ratio; TB: tuberculosis; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung
disease; PE: pulmonary embolism; PTB: pulmonary tuberculosis; EPTB: extrapulmonary tuberculosis.
#: adjusted for age, sex, UK born and HIV.
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address, although obtaining primary healthcare records from where patients were initially seen could
corroborate reported symptoms and durations. In addition, missing data occurred in a greater proportion
of older patients compared with younger patients. This is due to the different time periods, with more
radiography reports available in later time periods. However, given the magnitude of the differences noted,
this is unlikely to alter the results that are statistically significant.
In summary, our analysis of data from a large UK cohort of TB patients has demonstrated different
clinical and radiological presentations between older and younger TB patients, and longer time to TB
treatment for older patients, which was a cumulative effect of longer time to presentation and longer time
from presentation to initiation of treatment. These differences may relate to the lower index of suspicion
of TB in the elderly, but also to the effect of immunosenescence on the classical presentations of TB.
These findings relate to an urban cohort that had a high burden of TB during the study period in a
country that has a low incidence of TB and they will be applicable in similar settings in Western Europe.
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